# Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

> **NCT02315625** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Neuroendocrine Neoplasms
- Carcinoma, Neuroendocrine
- Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT02315625
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-08
- **Primary completion:** 2019-05-22
- **Final completion:** 2019-05-22
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study closed due to poor accrual.
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315625, "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02315625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*